SUZHOU, China – Chinese CAR T therapy developers from early to IPO-ready-stage are confident that they can create a strong presence in the global scene with their innovations, and they are also making strategies that will work best for their home market.

Data presented at the American Society of Clinical Oncology’s annual meeting.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abbvie, Aerpio, Alligator, Anixa, Astrazeneca, Beigene, Biogen, Biotheus, Bold, Carna, Ceapro, Chimeron, Codiak, Daiichi Sankyo, Edigene, Eli Lilly, Emergent, Fujifilm, Heat Biologics, Hitgen, Hua Medicine, Humanigen, Immunitybio, Immunochina, Immutep, Innovation, Jacobio, Kalytera, Mateon, Merck, Moderna, Nantkwest, Novavax, Oncodesign, Ontochem, Organicell, Orpro, Oryzon Genomics, Oxford Biomedica, Praha Vaccines, Proteona, Proteostasis, Puretech, Rakuten Medical, Restorbio, Resverlogix, Seranovo, Shanghai Junshi, Shionogi, Synairgen, Takeda, Tetra, Tolero, Tonix, Toshiba, Twist, Vault, Vir, Virna.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Abivax, Accord Healthcare, Akeso, Algernon, Altimmune, Anivive Lifesciences, Astellas, Beyond Air, Cerecor, Diffusion, Hutchison China Meditech, Immunitybio, Longeveron, Moleculin, Opko Health, Orpheris, Phasebio, Qurient, Radius Health, Shanghai Henlius, Shionogi, Sino, Takeda, Teijin.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Apellis, Atriva, Belx Bio-Pharmaceutical (Taiwan), Calcimedica, CTI Biopharma, Genentech, Gilead Sciences, Glenmark, I-Mab, Mesoblast, Moderna, Novavax, NS Pharma, Partner, Radius Health, Synairgen, Taiwan Liposome, Teijin, Transcenta, Zai Lab.

The latest global regulatory news, changes and updates affecting biopharma, including: Blue Dog Coalition, FDA, U.S. House and Senate.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Genetic Technologies, Outlook, Pneumagen.